#United States #New York #Lucid Diagnostics #EsoGuard #Veterans Affairs

Landmark Contract between Lucid Diagnostics and the VA

In a significant development for cancer prevention efforts, Lucid Diagnostics Inc., a leader in medical diagnostics and a subsidiary of PAVmed Inc., has been awarded a contract by the U.S. Department of Veterans Affairs (VA). This agreement is aimed at broadening the availability of EsoGuard®, an innovative Esophageal DNA Test that targets the early detection of esophageal precancer. This advancement is set to benefit over nine million veterans who rely on the vast services provided by the VA each year.

Understanding EsoGuard®

EsoGuard® is at the forefront of cancer preventive diagnostics, specifically designed to identify precancerous conditions in patients suffering from gastroesophageal reflux disease (GERD). This ailment, commonly known as chronic heartburn, poses an increased risk of developing esophageal cancer. The test is non-invasive and can be administered in a standard medical office visit, using the EsoCheck® Esophageal Cell Collection Device. This makes the process both efficient and manageable for patients, while promoting early detection.

With the new contract, the EsoGuard® test will be integrated into the VA's extensive healthcare system, allowing for easier access to this crucial testing method through a unified national procurement framework. The pricing for EsoGuard® has been pre-negotiated to align with Medicare rates, ensuring that VA facilities can conveniently utilize the test without the burden of additional costs or complicated logistics.

Quote from Leadership

Shaun O'Neil, Lucid Diagnostics' President and Chief Operating Officer, expressed pride in the partnership: "We are proud to partner with the U.S. Department of Veterans Affairs to expand access to EsoGuard for our nation's veterans. The VA operates at significant clinical and operational scale, and selection by a healthcare system of this size reflects the strength of the clinical evidence supporting EsoGuard.” This statement emphasizes the importance of clinical evidence in gaining the trust of major healthcare organizations like the VA.

Implications of the Contract

This partnership represents a pivotal moment for veterans’ healthcare, especially considering that esophageal cancer often goes undetected until it reaches advanced stages. By implementing EsoGuard®, veterans will have improved access to essential preventive care, ultimately leading to better health outcomes. Furthermore, Lucid Diagnostics aims to engage additional healthcare systems across the nation, with the hope of integrating this vital testing into standard clinical practice comprehensively.

About Lucid Diagnostics

Lucid Diagnostics is deeply invested in the mission to reduce cancer incidence through early detection methods. As a commercial-stage cancer prevention medical diagnostics firm, it focuses on advancing technology that assists patients at risk. By taking proactive steps to implement screenings through initiatives such as the VA contract, Lucid underscores its commitment to protecting the health of individuals at risk of serious conditions.

For more information about Lucid Diagnostics and its key offerings, interested parties are encouraged to visit www.luciddx.com. Additional details about its parent company, PAVmed, can be found at www.pavmed.com.

Conclusion

The contract between Lucid Diagnostics and the U.S. Department of Veterans Affairs symbolizes a major step towards enhanced healthcare access for veterans. It highlights the necessity of implementing advanced diagnostic tools in public health frameworks to ensure early detection and intervention in cases of potential cancer. As the landscape of medical diagnostics continues to evolve, partnerships like these pave the way for improved preventative care for those who have served their country.